Insights into how the first vaccine ever reported to modestly prevent HIV infection in people might have worked were published online today in the New England Journal of Medicine. Scientists have found that among adults who received the experimental HIV vaccine during the landmark RV144 clinical trial, those who produced relatively high levels of a specific antibody after vaccination were less likely to get infected with the virus than those who did not. The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, co-funded the research.

Related posts:

  1. H1NI? Higher Dose of Seasonal Flu Vaccine Provides Extra Protection Higher Dose of Seasonal Flu Vaccine Provides Extra Protection ...
  2. Medicare Card, NIH study finds factors that may influence influenza vaccine effectiveness Medicare Card, NIH study finds factors that may influence influenza vaccine effectiveness...
  3. Medicare Card, NIH begins testing investigational Zika vaccine in humans Medicare Card, NIH begins testing investigational Zika vaccine in humans...
  4. Medicare, Funded HIV clinical research sites to join pediatric tuberculosis vaccine study Several U.S. government-funded HIV/AIDS clinical research sites in Africa will join other collaborators in an ongoing clinical trial testing an investigational tuberculosis (TB) vaccine in infants at risk for TB infection. “We are pleased to be able to tap into our existing HIV/AIDS clinical research infrastructure to help test promising investigational vaccines against TB,” said […]...
  5. Medicare Card, NIH launches early-stage yellow fever vaccine trial Yellow fever virus is found in tropical and subtropical, and caused an estimated 29,000 to 60,000 deaths in 2013. The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has begun an early-stage clinical trial of an investigational vaccine designed to protect against yellow fever virus. The Phase 1 […]...
  6. Medicare Card,NIH scientists develop candidate vaccine against respiratory syncytial virus An experimental vaccine to protect against respiratory syncytial virus (RSV), a leading cause of illness and hospitalization among very young children, elicited high levels of RSV-specific antibodies when tested in animals, according to a report in the journal Science....
  7. Priming with DNA vaccine makes avian flu vaccine work better The immune response to an H5N1 avian influenza vaccine was greatly enhanced in healthy adults if they were first primed with a DNA vaccine expressing a gene for a key H5N1 protein, researchers say. Their report describes results from two clinical studies conducted by researchers from the National Institute of Allergy and Infectious Diseases (NIAID), […]...
  8. Medicare Card, Testing of investigational inactivated Zika vaccine in humans begins Medicare Card, Testing of investigational inactivated Zika vaccine in humans begins...
  9. Medicare Card, Investigational malaria vaccine protects healthy U.S. adults for more than one year Medicare Card, Investigational malaria vaccine protects healthy U.S. adults for more than one year...
  10. NIH Scientists Advance Universal Flu Vaccine A universal influenza vaccine — so-called because it could potentially provide protection from all flu strains for decades — may become a reality because of research led by scientists from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health....
  11. Medicare Card, NIH scientists map first steps in flu antibody development Medicare Card, NIH scientists map first steps in flu antibody development...
  12. Chikungunya vaccine trial begins to enroll participants An experimental vaccine to prevent chikungunya fever, a viral disease spread by certain species of mosquitoes, is being tested in a clinical trial conducted by National Institute of Allergy and Infectious Diseases (NIAID) scientists at the National Institutes of Health....
  13. Medicare Card, NIH-developed candidate dengue vaccine shows promise in early-stage trial Medicare Card, NIH-developed candidate dengue vaccine shows promise in early-stage trial...
  14. Medicare Card, Large-scale HIV vaccine trial to launch in South Africa Medicare Card, Large-scale HIV vaccine trial to launch in South Africa...
  15. HIV Vaccine Awareness Day May 18, 2011 Thirty years since the first report of the disease we now know as AIDS, scientists supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, continue advancing toward our goal of a vaccine to prevent HIV infection. I am optimistic that we will succeed....